Managing scientific and regulatory documentation is a major challenge for the pharmaceutical industry, where delays can postpone the market launch of treatments and, consequently, hinder patients’ access to life-saving therapies. Addressing this issue, Paris-based startup Biolevate offers ELISE, a platform that leverages artificial intelligence to revolutionize how medical documents are created, managed, and optimized.
Founded in 2023 by Joël Belafa (CEO), a former executive at Dataiku and expert in AI for enterprises, Nathan Chen (COO), formerly at Coloplast, and Anas Laaroussi (CTO) and Antoine De Torcy (CPO), the team combines deep expertise in artificial intelligence with an in-depth understanding of pharmaceutical processes.
ELISE: AI-powered excellence in scientific documentation
The ELISE platform (Elevate Literature Intelligence for Scientific Excellence) uses advanced technologies such as natural language processing (NLP) and computer vision to enhance every stage of the documentation lifecycle.
Key features include:
- Generation of compliant documents: Reducing the risk of regulatory errors.
- Document search and monitoring: Quickly identifying critical information in scientific literature.
- Collaboration and tracking: Integrating feedback and tracking edits for seamless project management.
- Automated analysis: Extracting metadata, ensuring compliance, and predicting potential risks.
This AI-driven approach ensures traceable results through a “human-in-the-loop” system, enabling users to validate and understand each decision made by the platform.
A funding round to fuel growth
To support its ambitions, Biolevate has raised €6 million in a Seed funding round led by EQT Ventures. This financial backing will allow the startup to expand its team, enhance the technological development of the ELISE platform, and establish a presence in new strategic markets.
